bendamustine hydrochloride has been researched along with Leukocytopenia in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 1 (9.09) | 2.80 |
Authors | Studies |
---|---|
Ennishi, D; Fujii, S; Fujiwara, Y; Hiramatsu, Y; Imai, T; Maeda, Y; Nawa, Y; Niiya, D; Sunami, K; Urata, T; Yano, T; Yoshida, I | 1 |
Chinen, Y; Fuchida, SI; Horiike, S; Iwai, T; Kaneko, H; Kawata, E; Kiyota, M; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakao, M; Nishigaki, H; Ohshiro, M; Shimazaki, C; Shimura, K; Shimura, Y; Sugitani, M; Takimoto-Shimomura, T; Taniwaki, M; Uchiyama, H; Uoshima, N; Yoshida, M | 1 |
Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
Aisa, Y; Chen, K; Hagihara, M; Ishida, A; Masuda, Y; Matsumoto, K; Miyakawa, Y; Nakajima, H; Nakaya, A; Nakazato, T; Okamoto, S; Shimizu, T; Takayama, N; Tsukada, Y; Ueno, H; Watanabe, K; Yamada, Y; Yano, T; Yokoyama, K | 1 |
Knauf, W | 1 |
Wilkes, GM | 1 |
Ando, K; Kasai, M; Matsumoto, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimizu, D; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T; Yokoyama, H | 1 |
Ando, K; Choi, I; Ishizawa, K; Itoh, K; Kubota, N; Nagai, H; Ogura, M; Ohmachi, K; Terui, Y; Tobinai, K; Uchida, T; Uike, N; Uoshima, N; Usuki, K; Watanabe, T; Yamamoto, J | 1 |
Cheson, BD; Friedberg, JW; Kahl, BS; Tremmel, L; Van der Jagt, RH | 1 |
D'Amore, ES; Finotto, S; Menin, A; Paolini, R; Pizzolo, G; Rodeghiero, F; Semenzato, G; Visco, C; Zaja, F; Zambello, R; Zanotti, R | 1 |
Höffken, K; Klippstein, A; Sayer, HG; Schneider, CP | 1 |
1 review(s) available for bendamustine hydrochloride and Leukocytopenia
Article | Year |
---|---|
Bendamustine in the treatment of chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Nitrogen Mustard Compounds; Treatment Outcome | 2009 |
5 trial(s) available for bendamustine hydrochloride and Leukocytopenia
Article | Year |
---|---|
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytomegalovirus Infections; Dexamethasone; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Rituximab; Salvage Therapy; Young Adult | 2019 |
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2015 |
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lung Diseases, Interstitial; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Neutropenia; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2010 |
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Pneumonia; Recurrence; Treatment Outcome; Vomiting | 2010 |
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Positron-Emission Tomography; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vomiting | 2013 |
5 other study(ies) available for bendamustine hydrochloride and Leukocytopenia
Article | Year |
---|---|
Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hematology; Humans; Incidence; Leukopenia; Lymphoma, Follicular; Male; Retrospective Studies; Rituximab; Thrombocytopenia | 2022 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Drug essentials. An alkylating agent for CLL and NHL.
Topics: Alkylating Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Fatigue; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Patient Education as Topic | 2009 |
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Nitrogen Mustard Compounds; Rituximab; Survival Analysis; Treatment Outcome | 2010 |
Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Fatal Outcome; Female; Humans; Leukopenia; Middle Aged; Nitrogen Mustard Compounds; Pneumonia, Pneumocystis; Respiratory Insufficiency; Treatment Failure | 2003 |